Evidence map›Paper›PMID 33524500›Full record

ArticleCancer letters2021

In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation.

Yueying Liu, Jing Yang, Zonggao Shi, Xuejuan Tan, Norman Jin, Catlin O'Brien, Connor Ott, Anna Grisoli, Eric Lee, Kelly Volk and 18 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Adhesion molecule Amigo2 is involved in the fasciculation process of the fasciculus retroflexus.Developmental dynamics : an official publication of the American Association of Anatomists · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 1 institution in 2 countries.

Yueying LiuDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Jing YangDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Zonggao ShiHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA; St. Jude Children's Research Hospital, Memphis, TN, USA.
Xuejuan TanHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Norman JinHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Catlin O'BrienHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Connor OttHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Anna GrisoliHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Eric LeeHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Kelly VolkHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Meghan ConroyHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Emily FranzHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Annamarie BryantHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Leigh CampbellHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Brian CrowleyHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Stephen GrisoliHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Aris T AlexandrouHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA; Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Chunyan LiHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA; Department of Gynecology, Shandong Provincial Hospital, Shandong First Medical University, Jinan, China.
Elizabeth I HarperDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Marwa AsemDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Jeff JohnsonDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Annemarie LeonardHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Katie SantanelloHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Ashley KleinHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Qingfei WangHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Siyuan ZhangHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Tyvette S HilliardDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
M Sharon StackDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA. Electronic address: sstack@nd.edu.
University of Notre Dame · US

Funding

Receptor Cross-Talk in Early Metastatic DisseminationR01CA109545 · NCI · UNIVERSITY OF NOTRE DAME · PI STACK, MARY SHARON · 2006 to 2022
$4.3M
Chemistry-Biochemistry-Biology Training Program at Notre DameT32GM075762 · NIGMS · UNIVERSITY OF NOTRE DAME · PI CHANG, MAYLAND F, MOBASHERY, SHAHRIAR · 2007 to 2021
$3.7M
(PQD-3) Spatiotemporal Molecular Interrogation of Early Metastatic Evolution In SituR01CA194697 · NCI · UNIVERSITY OF NOTRE DAME · PI ZHANG, SIYUAN · 2015 to 2018
$1.4M
The Impact of Maternal Obesity on the Reprogramming of the Metastatic MicroenvironmentK01CA218305 · NCI · UNIVERSITY OF NOTRE DAME · PI HILLIARD, TYVETTE · 2017 to 2021
$517k
Integrative Analysis of the Aging Peritoneum in Metastatic ReceptivityF99AG068527 · NIA · UNIVERSITY OF NOTRE DAME · PI HARPER, ELIZABETH · 2020 to 2021
$93k
NCI NIH HHS K01 CA218305NCI NIH HHS R01 CA109545NCI NIH HHS R01 CA194697NIA NIH HHS F99 AG068527NIGMS NIH HHS T32 GM075762
6 · The paper itself

Abstract

The majority of women with ovarian cancer are diagnosed with metastatic disease, therefore elucidating molecular events that contribute to successful metastatic dissemination may identify additional targets for therapeutic intervention and thereby positively impact survival. Using two human high grade serous ovarian cancer cell lines with inactive TP53 and multiple rounds of serial in vivo passaging, we generated sublines with significantly accelerated intra-peritoneal (IP) growth. Comparative analysis of the parental and IP sublines identified a common panel of differentially expressed genes. The most highly differentially expressed gene, upregulated by 60-65-fold in IP-selected sublines, was the type I transmembrane protein AMIGO2. As the role of AMIGO2 in ovarian cancer metastasis remains unexplored, CRISPR/Cas9 was used to reduce AMIGO2 expression, followed by in vitro and in vivo functional analyses. Knockdown of AMIGO2 modified the sphere-forming potential of ovarian cancer cells, reduced adhesion and invasion in vitro, and significantly attenuated IP metastasis. These data highlight AMIGO2 as a new target for a novel anti-metastatic therapeutic approach aimed at blocking cohesion, survival, and adhesion of metastatic tumorspheres.

Indexed as

Up-RegulationAnimalsCell AdhesionCell Line, TumorCell MovementCell SurvivalFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMiceMutationNeoplasm TransplantationNerve Tissue ProteinsOvarian NeoplasmsPeritoneal NeoplasmsAMIGO2 protein, humanNerve Tissue ProteinsTP53 protein, humanTumor Suppressor Protein p53AMIGO2Intra-peritoneal metastasisInvasion]Multi-cellular aggregateOvarian cancerSpheroidTumorsphere [deleted adhesion

Identifiers

PMID33524500
PMCPMC7981259
OpenAlexW3127712181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.